Clinical efficiency Cognivia focuses on reducing trial data variability by up to 30%, enabling smaller studies with lower cost and shorter timelines. This presents a strong value case for sponsors seeking faster, cost-efficient development and earlier market access.

Placebo insight Placebell, Cognivia’s solution for characterizing and managing individual placebo responses across disease states, targets a key risk area in trials where placebo effect obscures true efficacy, offering a compelling differentiator to improve trial success rates.

AI driven growth As an AI-enabled analytics provider with recent multi-million funding, Cognivia has the capital to scale its platform, expand client access, and invest in pipeline tools that address high-variability, costly trial endpoints appealing to mid-to-large pharma and biotech firms.

Strategic partnerships Participation in industry conferences such as SAPA signals active business development motion and networking opportunities with potential partners and sponsors, suggesting a ready-made channel to engage CROs, sponsors, and contract research networks.

Geographic and market fit Based in Belgium with global IP appeal and a focus on clinical development analytics, Cognivia can target multinational pharmaceutical companies seeking regional access plus scalable tools for diverse geographies, potentially expanding into North American and EU markets.